Abstract library

174 results for "cumulative dose".
#1578 Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors
Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Prof. Rossana Berardi
#840 Clinical Impact of Everolimus Cumulative Dose on Pancreatic Neuroendocrine Tumors (pNETs) Outcome
Introduction: Everolimus is approved for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Rossana Berardi
#781 Effect of Mean Absorbed Renal Dose on the Renal Function After Peptide Receptor Radionuclide Therapy
Introduction: Kidneys are the critical organs in peptide receptor radionuclide therapy (PRRNT) of neuroendocrine neoplasms (NENs).
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr. Harshad Kulkarni
#1534 Personalized 177Lu-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) Allows a Safe and Significant Increase of Radiation Dose to Neuroendocrine Tumors (NETs)
Introduction: 177Lu-octreotate PRRT is commonly administered at fixed/empiric activity per cycle, which results in highly variable radiation doses to critical organs and undertreatment of the majority of patients.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Michela Del Prete
#1817 Dosimetric Analyses of Patients with Metastatic Gastrointestinal Neuroendocrine Tumors Treated with PRCRT Using 177 Lu-DOTATATE with Capecitabine as Radiosensitizer
Introduction: Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE is gaining acceptance as safe and effective therapy for inoperable neuroendocrine tumors (NET). A radiosensitizing chemotherapeutic drug -capecitabine, the prodrug of 5-Flourouracil, is included in the protocol to further enhance therapeutic efficacy.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: DNB, FEBNM Sugandha Dureja
Authors: Dureja S, Thakral P, Pant V, Pallavi U, ...
Keywords: PRRT, radiosensitizer
#1388 Nephrotoxicity after PRRT with 177Lu-DOTA-Octreotate
Introduction: Renal toxicity may occur after Peptide Receptor Radionuclide Therapy (PRRT). Risk factors have been identified for renal toxicity after 90Y based PRRT.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Hendrik Bergsma
#1538 Safety of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial
Introduction: Dose escalation (or interval reduction) of somatostatin analogs (SSAs) is a rather common strategy for patients (pts) with progressive metastatic neuroendocrine tumors (NETs). However, to date, no systematic prospective studies have been carried out to evaluate safety and efficacy of this treatment schedule in NETs.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD, PhD Manuela Albertelli
#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#588 CORRELATION OF TUMOR ABSORBED DOSES OF 177LU-DOTA-TATE TREATMENT WITH PRE-THERAPEUTIC GA68 DOTA-TATE PET/CT UPTAKE IN NEUROENDOCRINE TUMORS
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 aroused great interest. Estimation of actual radiation doses to tumors may help therapy planning.
Conference:
Category: Clinical
Presenting Author: Dr. Demirci Emre
Authors: demirci E, kabasakal L, toklu T, ocak M, ...
#1155 Evaluation of Features and Predictors for Long Term Hematologic Toxicity in Neuroendocrine Patients Treated with Peptide Receptor Radionuclide Therapy
Introduction: Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET) may offer partial or complete objective response in up to 30% of patients. To deliver treatment in a safe and effective manner, long term adverse events should be considered.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Suzanne Richter
Keywords: PRRT